Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 17Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Mesothelioma 2Melanoma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

azaspirane 2atezolizumab 2Everolimus 2Cisplatin 2tocilizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1durvalumab 1budigalimab 1Paclitaxel 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1IFL protocol 1Fluorouracil 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Neuroendocrine × budigalimab × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡